申请人:Taisho Pharmaceutical Co., Ltd
公开号:US08022225B2
公开(公告)日:2011-09-20
A compound represented by the formula (I) below or a pharmaceutically acceptable salt thereof has an effect of inhibiting binding between S1P and its receptor Edg-1(S1P1), and is useful as a pharmaceutical product.
[where
A represents a sulfur atom, an oxygen atom, a formula —SO— or a formula —SO2—; R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or the like; R2 represents an alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 8 carbon atoms or the like; R3 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; R4 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a phenyl group or the like; R5 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; and R6 represents an alkyl group having 1 to 6 carbon atoms, a phenyl group or a substituted phenyl group].
化合物(I)或其药学上可接受的盐,具有抑制S1P与其受体Edg-1(S1P1)结合的效果,可用作药物产品。其中,A代表硫原子、氧原子、公式—SO—或公式—SO2—;R1代表氢原子、具有1至6个碳原子的烷基或类似物;R2代表具有1至6个碳原子的烷基、具有3至8个碳原子的环烷基或类似物;R3代表氢原子或具有1至6个碳原子的烷基;R4代表氢原子、具有1至6个碳原子的烷基、苯基或类似物;R5代表氢原子或具有1至6个碳原子的烷基;R6代表具有1至6个碳原子的烷基、苯基或取代苯基。